Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics

(1) Background: The oncology field has drastically changed with the advent of precision medicine, led by the discovery of druggable genes or immune targets assessed through next-generation sequencing. Biomarker-based treatments are increasingly emerging, and currently, six tissue-agnostic therapies...

Descripción completa

Detalles Bibliográficos
Autores principales: Tateo, Valentina, Marchese, Paola Valeria, Mollica, Veronica, Massari, Francesco, Kurzrock, Razelle, Adashek, Jacob J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144220/
https://www.ncbi.nlm.nih.gov/pubmed/37111371
http://dx.doi.org/10.3390/ph16040614

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144220/
https://www.ncbi.nlm.nih.gov/pubmed/37111371
http://dx.doi.org/10.3390/ph16040614

Ejemplares similares